青島雙星(000599.SZ):股票期權激勵計劃取得批覆
格隆匯 11 月 10日丨青島雙星(000599.SZ)公佈,公司於2020年11月10日收到控股股東雙星集團有限責任公司轉來的青島城市建設投資(集團)有限責任公司出具的《關於青島雙星股份有限公司股票期權激勵計劃的批覆》(青城投字[2020]130號),批覆主要內容如下:
一、原則同意青島雙星股份有限公司股票期權激勵計劃。
二、雙星集團有限責任公司要按照國有控股上市公司股權激勵相關規定,規範實施股權激勵計劃,指導上市公司科學合理確定激勵對象、權益數量、權益價格,設置體現前瞻性、挑戰性業績目標,充分調動核心骨幹人才創新創業積極性,共享企業改革發展成果,促進青島雙星股份有限公司健康可持續發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.